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ABSTRACT
Immunotherapy for metastatic melanoma offers great promise but, to date, only 
a subset of patients have responded. There is an urgent need to identify ways of 
allocating patients to the most beneficial therapy, to increase survival and decrease 
therapy-associated morbidity and costs. Blood-based biomarkers are of particular 
interest because of their straightforward implementation in routine clinical care. 
We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy 
against metastatic melanoma through gene expression analysis of peripheral 
blood mononuclear cells. A large-scale microarray analysis of 74 samples from 
two treatment centers, taken directly after the first round of DC vaccination, was 
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performed. We found that phosphatidylethanolamine binding protein 1 (PEBP1)/ 
Raf Kinase inhibitory protein (RKIP) expression can be used to identify a significant 
proportion of patients who performed poorly after DC vaccination. This result was 
validated by q-PCR analysis on blood samples from a second cohort of 95 patients 
treated with DC vaccination in four different centers. We conclude that low PEBP1 
expression correlates with poor overall survival after DC vaccination. Intriguingly, 
this was only the case for expression of PEBP1 after, but not prior to, DC vaccination. 
Moreover, the change in PEBP1 expression upon vaccination correlated well with 
survival. Further analyses revealed that PEBP1 expression positively correlated with 
genes involved in T cell responses but inversely correlated with genes associated 
with myeloid cells and aberrant inflammation including STAT3, NOTCH1, and MAPK1. 
Concordantly, PEBP1 inversely correlated with the myeloid/ lymphoid-ratio and was 
suppressed in patients suffering from chronic inflammatory disease.
INTRODUCTION
Metastatic melanoma is one of the most devastating 
types of cancers in terms of potential life-years lost and 
affects a growing number of patients each year [1, 2]. 
Currently, there are different types of immunotherapy 
that may offer long-term benefit for melanoma patients. 
These therapies are based on: 1) antagonists of molecules 
that suppress pre-existing anti-tumor immune responses, 
so-called immune checkpoint inhibitors such as anti-
CTLA-4 (ipilimumab) and anti-PD-1/PD-L1 antibodies 
(nivolumab/pembrolizumab/atezolizumab); 2) delivery 
of autologous ex vivo expanded tumor infiltrating 
lymphocytes to boost anti-tumor T cell response; 3) 
oncolytic viruses injected into metastases to lyse tumor 
cells and enhance immune responses; and 4) ex vivo or 
in vivo targeting of dendritic cell (DCs) to initiate and/or 
boost tumor antigen-specific immune responses (reviewed 
in [3, 4]). These new immunotherapies, however, are 
extremely expensive and/or labor intensive due to high 
production costs and/or the need for patient-personalized 
preparation. In addition, although these therapies offer 
clear benefit for a group of patients, there are also many 
primary and secondary non-responders [5–7]. This is 
illustrated by the fact that individual melanoma patients 
can respond very well to immunotherapy, but those that 
do represent a limited proportion of the total number who 
receive this treatment [8–13]. Markers to determine which 
patients do, or do not, benefit are therefore urgently needed 
to facilitate treatment decisions. In particular, mechanism 
of action-based markers, derived from our understanding 
of why specific treatments are beneficial or not in certain 
patient populations, have a high potential [7].
So far, a number of prognostic factors for survival 
in melanoma have been defined, together with several 
markers associated with or predicting responses to 
various forms of therapy [14–17]. The success of 
many immunotherapies is thought to be associated 
with the composition and organization of the tumor 
microenvironment, and therefore biomarkers are often 
sought in this respect [18]. Indeed several studies 
have identified tumor properties that have correlated 
the with outcome of immunotherapies, including the 
expression of cytokines (interferon-γ), chemokines 
(CCL5, CXCL9, CXCL10), immunoregulatory molecules 
such as indolamine-2,3-dioxygenase [8, 19] and, more 
recently, tumor expression of PD-L1 that was reported 
to be predictive for responses to checkpoint inhibitors in 
melanoma [20].
Many of the potential biomarkers for immunotherapy 
against melanoma, reported so far, have been tissue based. 
This severely limits their clinical applicability because 
for many patients the primary tumor is not or no longer 
available, and metastatic tumor tissue material can 
also be hard to obtain. Furthermore, intra-individual 
heterogeneity of tissue biomarker expression (i.e. 
between different metastases and/or with respect to 
the primary tumor) may limit reliability [21]. These 
factors can severely limit the predictive effectiveness 
of a biomarker and, more importantly, may lead to 
the incorrect exclusion of patients from a potentially 
effective therapy. Furthermore, tissue biomarkers can 
only be assessed at one single time point. In contrast, 
blood-based markers can potentially overcome all these 
issues. Diagnostic liquid biopsies have already been used 
in breast cancer, colorectal cancer and in non-small cell 
lung cancer [22–24]. Moreover, blood samples are being 
utilized for cell-based cancer-detection in plasma and for 
tumor mutational analyses [24–26]. A major advantage 
of obtaining blood samples as a source of biomarkers 
for therapy prediction is that it is a minimally-invasive 
intervention which allows the tracking of disease 
dynamics during the course of treatment.
For dendritic cell DC vaccination specifically, 
efforts have been made to identify markers associated with 
patient responses to therapy [27, 28]. In our laboratory, we 
have developed a delayed type hypersensitivity response 
(DTH) test to assess the induction of tumor-specific T cells 
in response to DC vaccination into the skin [29, 30]. This 
showed that the induction of antigen-specific T cells by 
DC vaccination was associated with improved survival. 
However the absence of detection of tumor-reactive T 
cells did not necessarily indicate a poor response, and 
therefore additional methods to predict whether a patient 
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will benefit from DC therapy are required. Here we have 
used microarray analysis of peripheral blood mononuclear 
cells (PBMCs) from treated patients to identify biomarkers 
that can be used to monitor and further improve our 
understanding of the response to DC vaccination. 
Using this strategy we have identified and validated 
phosphoethanolamine binding protein 1 (PEBP1), also 
known as Raf-1 kinase inhibitor protein (RKIP), as a 
biomarker that can be used to predict patient survival after 
DC vaccination. PEBP1 has previously been described to 
modulate several major cancer and inflammatory signaling 
pathways [31–34]. Here, further in-depth analysis of the 
genes that are co-expressed with PEBP1 suggests that 
its increased expression after vaccination is indicative of 
the beneficial skewing of the adaptive immune system 
towards an effective anti-tumor response.
RESULTS
Selection of genes with prognostic potential from 
microarray data of PBMCs from treated patients
To identify biomarkers in the blood of treated 
patients that may correlate with survival after DC 
vaccination, we analyzed PBMCs from a total of 74 
patients by microarray (MA). These patients had been 
treated with DC vaccination in two different centers 
(Discovery cohort; Nijmegen and Erlangen). Only 
PBMC samples taken after vaccination were at our 
disposal in sufficient numbers to allow MA-based 
comparison of good and poor responders. In search 
of a reasonably-sized set of potential biomarkers that 
allowed validation by qPCR, we performed several 
different statistical analyses, including survival 
analysis, statistical analysis of microarray (SAM) as 
well as multivariate analysis (PLS-DA; Supplementary 
Figure 1). For survival analysis, expression data 
were related to survival time after the start of DC 
vaccination in a continuous manner. For SAM and 
PLS-DA, patients were grouped into three survival 
subgroups [short (<1 year); medium (1-2 years), and 
long (>2 years); Table S1)], to allow us initially to 
search for gene expression differences between the 
extremes of this survival spectrum. For SAM, we 
extracted probes with expression values satisfying two 
criteria: (i) significant differences between patients 
from the short and long survival subgroups; and (ii) 
significant differences between PBMCs and vaccine 
DCs of the same donor (to increase the chance of 
finding biomarkers related to a specific cell type and/ 
or immune response). For all three methods, a final 
filter taking at least a 2-fold change in expression 
levels between the short and long survival subgroups 
was applied (Supplementary Figure 1). These three 
approaches resulted in relatively large lists ranging 
from 62 to 307 candidates that all may have potential 
prognostic value. To further reduce the list to a size 
compatible with qPCR validation, only the candidates 
that emerged from all three approaches were retained. 
This final list consisted of 19 genes (Table 1).
Validation of microarray analysis results by 
qPCR
Next, we set out to verify MA results using qPCR. 
For MA analysis we had chosen to use as many datasets 
as possible in order to find the most robust differentially-
expressed genes across treatment centers, and to add 
power to the statistical analysis. This strategy, however, 
posed the risk of a center effect since the samples from the 
two treatment centers were not fully comparable in terms 
of patient composition and timing of sample collection 
(methods and supplementary tables S1-S3). In addition, 
while stage IV patients comprised the majority, stage III 
melanoma patients had also been included (Supplementary 
table S1 and S2). Thus, to exclude any confounding effects 
of these dissimilarities, only Nijmegen-center stage IV 
patients were used for the initial qPCR validation of 
the MA result and for the subsequent selection of qPCR 
validated genes. For 28 patients within this group, we first 
directly compared the MA data to the qPCR data obtained, 
to assess which genes behaved most consistently using 
these very different techniques. Out of 19 genes derived 
by MA, 11 showed a significant and positive correlation 
with the qPCR measurement (Supplementary information 
Figure 2 & Table 1 ).
We then assessed whether the expression of any 
of the above qPCR-validated genes also correlated 
with survival. After correction for multiple testing, four 
genes out of the 11 passed this criterion (Supplementary 
information Figure 3 & Table 1 ). Only one of these 
genes, PEBP1 (RKIP) correlated positively with patient 
survival; the remaining three, FCGR1B (CD64), ANXA2 
(Annexin-2) and FCGR1B (Fcγ-receptor 1B, CD64), 
correlated negatively (Table 1). Hence these four genes 
could potentially predict clinical outcomes and/or provide 
mechanistic insights into the mechanisms of patient 
responses to DC therapy.
Validation of differential expression of selected 
genes between patient groups by qPCR
We wished to further assess and validate the 
association of the above 4 genes with patient survival 
after DC vaccination. Therefore we tested their expression 
on a second novel set of samples derived from Nijmegen 
patients that had not been used for MA gene selection, 
and on a completely independent set of samples derived 
from Copenhagen, a third treatment center exploiting DC 
vaccination. Interestingly, for PEBP1 the expected positive 
correlation with survival time, as well as a significantly 
lower expression in PBMCs from short surviving patients, 
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was observed in validation samples from both treatment 
centers (Figure 1). Also, additional samples not used for 
MA from the Erlangen treatment center showed a similar 
trend for PEBP1 despite the fact that the timing of sample 
collection was very different from the other two treatment 
centers (Supplementary Figure 4, methods). Unfortunately, 
insufficient samples from short survivors were available 
from Erlangen to draw any firm conclusions. For 
FCGR1B, a trend for negative association with survival 
was observed, but only in the Nijmegen validation cohort 
(Figure 1). However, the association of ANXA2 and IMPA2 
could not be confirmed in any of these samples: they were 
neither differentially expressed between long and short 
survivors in the additional Nijmegen samples, nor in the 
completely independent Copenhagen samples (Figure 1A 
and data not shown).
Assessment of the clinical value of PEBP1 as a 
biomarker
Having established that the patients performing poor 
after DC vaccination expressed lower levels of PEBP1 
in PBMCs acquired after vaccination, irrespective of 
the treatment center, we set out to quantify the efficacy 
of PEBP1 to discriminate short- and long-surviving 
patient populations. To this end, we first performed 
a normalization step based on the median value of 
PEBP1 measured on all samples from each center and 
subsequently merged all Nijmegen and Copenhagen 
data (Figure 2; Table S1 for patient numbers). We then 
correlated the normalized expression data from all 
patients with survival time. On this merged qPCR dataset, 
containing all stage IV patient samples from Nijmegen and 
Table 1: Validation of MA expression data by qPCR
Gene (Symbol) Pearson correlation 
MA / qPCR
p-value Spearman correlation 
to survival
p-value
FCGR1B 0.68 < 0,0001 -0.52 0.0023
ANXA2 0.47 0.0059 -0.46 0.0065
PEBP1 0.46 0.0064 0.46 0.0074
IMPA2 0.45 0.0086 -0.34 0.0407
MNDA 0.58 0.0006 -0.31 0.055
SLC4A7 0.49 0.004 0.29 0.0679
BST1 0.45 0.0078 -0.26 0.0898
MGST1 0.48 0.0048 -0.24 0.1074
ZNF467 0.38 0.0244 0.09 0.3288
OAS2 0.42 0.0136 -0.02 0.4637
UBE2L6 0.33 0.0428 0.02 0.4681
ATP1B3 0.20 0.1505 NA NA
FH 0.16 0.2113 NA NA
LILRA5 (primer 1)a 0.31 0.0527 NA NA
LILRA5 (primer 2)a 0.28 0.0779 NA NA
TPM3 (probe 1)b -0.16 0.2147 NA NA
TPM3 (probe 2)b -0.10 -0.0967 NA NA
SRSF6 0.01 0.4705 NA NA
MAT2B -0.04 0.4255 NA NA
PSMB9 -0.11 0.2933 NA NA
TLR6 0.14 0.2389 NA NA
For the total 28 samples from stage IV patients of the Nijmegen discovery cohort we calculated the correlation between 
the expression levels as measured by microarray analysis (MA) against those obtained by qPCR. For validated genes we 
also calculated the correlation between qPCR expression and survival time. Only FCGR1B, ANXA2, PEBP1 and IMPA2 
were validated (in bold). a Two different primers were tested. bTwo probes for this gene were put forward by our statistical 
pipeline. See also Supplementary Figures 2 and 3 for correlation plots. NA: Not analyzed.
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Copenhagen, we again observed a significant correlation of 
PEBP1 expression with survival, confirming the potential 
of PEBP1 as a biomarker (Figure 2A). By visualizing the 
total patient population in one plot, it became apparent 
that, while most well-responding patients displayed a 
high expression of PEBP1, poorly responding patients 
could be subdivided into two groups with either low or 
high PEBP1 expression. This indicates that while low 
PEBP1 expression for the vast majority of patients marks 
a poor clinical outcome after DC vaccination, high PEBP1 
expression does not necessarily indicate a good prognosis. 
Nevertheless, a low expression of PEBP1 after the first 
Figure 1: Validation on independent samples. Samples from Nijmegen (Nij) that had not been part of the microarray (MA) study 
(A) and samples from a third completely-independent treatment center, Copenhagen (Cop; B), were tested to validate the MA-predicted 
association with patient survival. Upper panels: expression (qPCR) versus survival time. Spearman r and p-value (one-tailed) are given. 
Lower panels: expression (qPCR) of indicated genes in short (<1 year) versus long (>1 year) surviving patients in the two treatment centers. 
p-value by t-test (one-tailed).
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set of vaccinations could identify potential non-responders 
early-on, and thus enable early change to alternative or 
additional treatment. To find the optimal cut-off level of 
PEBP1 expression and survival length to identify such 
patients, we generated receiver-operator curves (ROC). 
The ROCs were based on the predetermined 12-month 
cut-off (i.e. the short survival group). This ROC performed 
well [area under the curve (AUC) 0.67+/-0.053]. The 
correlation plot, however, indicated that a survival of 
14 months rather than 12 months best delineated the 
patients with low PEBP1 expression and low survival. 
Indeed, patient selection was further improved when the 
maximal survival time for the short survival group was 
extended to 14 months (Figure 2A). This yielded the 
largest differences between survival groups and a ROC 
curve with an AUC of 0.69+/-0.053 (Figure 2B & 2C). 
Figure 2: Expression of PEBP1 is of value for treatment decision. (A) Spearman correlation of center-normalized expression 
values for PEBP1 with survival time after DC vaccination (one-tailed p-value). Grey area: population of patients with low expression 
of PEBP1 (<-0.33) that have predominantly a limited survival. Specifically indicated are the original 12-month (dotted line) and the 
adjusted 14-month (broken line in bold) survival windows (B) Center-normalized expression of PEBP1 in all evaluated patient samples 
from Nijmegen and Erlangen (discovery and validation together; one-sides p-values by t-test). (C) Reciever Operater Curve (ROC) of all 
Nijmegen and Copenhagen samples combined to select short survivors based on low expression of PEBP1. (D) Kaplan-Meyer curve of 
patients having a PEBP1 expression level below or above -0.33 (2 log center normalized C(t)).
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Of note, similar or better results were obtained for each 
treatment center separately, yielding AUC of 0.67+/-
0.06 and 0.76+/-0.08 for Nijmegen and Copenhagen 
respectively (Supplementary Figure 5). Also, the Erlangen 
dataset showed the same trend (AUC 0.64+/-0.14) but 
the ROC result was not significant, likely because of the 
low number of short surviving patients in this cohort (7 
patients). Based on the ROC curve of all pooled samples 
we determined that a PEBP1 expression cut-off of -0.33 
(center normalized 2log(Ct)) allowed us to identify patients 
who were surviving less than 14 months after vaccination 
with a sensitivity of 46% and a specificity of 89%. Using 
this expression cut-off we were thus able to select a 
patient population with a significantly poorer clinical 
outcome after vaccination, that is unlikely to respond to 
further DC therapy in the applied format and which would 
be in immediate need of other or additional treatments 
(Figure 2D).
PEBP1 expression during the course of 
vaccination
We then investigated whether PEBP1 expression 
levels could be informative also before vaccination, 
and therefore studied the expression of PEBP1 over 
time. For this we used Copenhagen samples for which 
PBMCs were taken a few days before vaccination, after 
4 vaccinations and after 6 vaccinations. Intriguingly, there 
were no differences in the expression levels of short and 
long surviving patients in PBMCs before vaccination, 
indicating PEBP1 expression correlates with clinical 
outcome after vaccination but cannot a priori predict 
whether a patient will respond or not (Figure 3A & 3B). 
The difference in PEBP1 expression was further increased 
after two additional vaccinations (Figure 3B & 3C). 
Notably, we found that the change of PEBP1 in response 
to vaccination correlated better with survival time 
than the expression level of PEBP1 itself (Figure 3D). 
Interestingly, an effect of vaccination was seen both in 
the short- and long-surviving patients: in short-surviving 
patients PEBP1 levels decreased during the course of 
vaccination, whereas it increased in long survivors (Figure 
3C). A similar trend was also present in a few longitudinal 
samples available from a fourth, independent treatment 
center in Innsbruck (Figure 3E). Together these results 
suggest that the change in PEBP1 expression (change) is 
indicative of patient responses to DC vaccination using 
overall survival as an endpoint, and as such may provide 
a mechanistic insight into what determines a successful 
treatment response.
PEBP1 may indicate skewing of the immune 
response
To obtain further insights into how PEBP1 
expression may reflect the response to DC vaccination, we 
interrogated the original MA data to identify genes that 
that were positively or negatively correlated with PEBP1 
to understand more about the molecular context in which 
this protein may act. First, we analyzed genes ranked 
on their correlation with PEBP1, for the enrichment 
of previously described blood transcriptional modules 
(BTMs) using Gene set enrichment analysis (GSEA) [35–
37]. Interestingly, BTMs indicated that PEBP1 expression 
correlated well with genes associated with an adaptive 
immune response (e.g. T cells and their activation) as 
well as the regulation of transcription (Table 2; Figure 4). 
However, the negatively-correlated genes were enriched 
for those relating to myeloid cells (e.g. monocytes, 
neutrophils, and immature DCs) and inflammation.
In the search for more mechanistic insights, we 
subjected the genes that were positively- or negatively-
correlated with PEBP1 to protein-protein-interaction 
and gene ontology (GO) analyses. We found that genes 
correlating with PEBP1 expression mapped to extremely 
well-connected, mostly ribosomal, proteins, suggesting 
high protein synthesis (ability) in these patient samples. 
Negatively-correlating genes were clustered around 
the signaling proteins STAT3, NOTCH1, MAPK1 and 
UBB (Figure 4). Moreover, these genes mapped to GO 
terms relating to antigen processing and presentation and 
the response to stress (supplementary Table S5), and in 
addition to the innate immune response as previously 
also indicated by GSEA. Together these results indicate 
that low PEBP1 may represent a state of systemic 
inflammation and stress accompanied by low protein 
biosynthesis. This systemic state may hamper an effective 
response to DC vaccination.
To investigate whether these functional implications 
of PEBP1 expression may stretch beyond DC vaccination 
and/ or metastatic melanoma, we interrogated a large co-
expression database of immune cells (immune-navigator) 
and found that also in this database PEBP1 expression 
correlated with adaptive immune cell responses and anti-
correlated with monocytes and generic immune activation 
(Figure 4 and supplementary table S6). Moreover, further 
analysis of publicly available blood or PBMC expression 
data comparing healthy subjects to those suffering 
from chronic inflammatory diseases (e,g Ankylosing 
spondylitis, Schnitzler syndrome and rheumatoid arthritis) 
revealed that low PEBP1 expression may be a more 
frequent event associated with chronic inflammation than 
previously anticipated (Figure 4).
These data suggest that low PEBP1 expression after 
DC vaccination may reflect the ineffective development 
of a productive, adaptive immune response and instead 
may be associated with myeloid cells that can negatively 
regulate immune responses in a state of aberrant/ chronic 
inflammation. Recently, several studies have reported the 
deleterious effect of myeloid-derived suppressor cells 
(MDSCs) in melanoma and in response to DC vaccination 
[15, 17, 38, 39]. Indeed, we found that biobanked PBMCs 
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Figure 3: Change in PEBP1 expression correlates with survival after vaccination. (A-D) Expression of PEBP1 was assessed 
in Copenhagen patients prior to or after 4 or 6 rounds of vaccination. (A) Spearman correlation of PEBP1 at the 3 time-points (p-value one-
tailed). Respectively n=39 , n=38 and n=30 pre-, after 4 and after 6 vaccinations. (B) Expression of PEBP1 at each time-point in short (<14 
months) or long survivors (> 14 months). Ns= non-significant * p<0.05 ** p<0.01 by t-test (one-tailed). (C) Course of PEBP1 expression 
during successive rounds of vaccination in short and long survivors (Mean +/- SEM). (D) Spearman correlation of survival time with the 
change in PEBP1 expression with respect to the start of vaccination (p-value one-tailed ). E Change in PEBP1 expression in relation to 
survival in patient samples from Innsbruck (n=7 stage IV in black; n=2 stage III in red).
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from DC-vaccinated patients demonstrated a trend for the 
inverse relation between PEBP1 expression levels and 
MDSC frequencies in the Nijmegen samples. However, 
this relationship could not be confirmed for samples of the 
other centers, possibly due to the non-optimal conditions 
induced by sample freezing and differences in the MDSC 
identification strategy (Supplementary Figure 6). In 
search for an alternative way to further substantiate the 
notion that high PEBP1 expression may associate with 
high lymphocyte/ adaptive immune responses but low 
Figure 4: PEBP1 expression reflects metabolic and inflammatory state. (A and B) Examples of BTMs that were found enriched by 
GSEA in the genes correlating to PEBP1 in the microarray dataset. Genes positively correlated to PEBP1 (A) were enriched in BTMs related 
to T cell (activation), whereas those negatively correlating with PEBP1 were enriched in BTMs related to monocytes and general inflammation 
(A). (C and D) Protein-protein Interactions (PPI) present in the STRING database for the top 500 genes positively (C) or negatively correlating 
to PEBP1 (D). Shown are genes for which the STRING database reported an interaction with a high confidence score (0.7) and more than 
one connection. Gene symbols are only displayed for genes with at least 20 (left graph) or 10 connections (right graph). (E) Enrichment of 
genes from the T cell and monocyte module within a list of genes ranked on correlation with PEBP1 in the Immuno-Navigator database. F) 
Expression of PEBP1 in blood or PBMC samples of healthy donors versus patients suffering from Ankylosing spondylitis (AS; GDS5231), 
Schnitzler syndrome (SS; GSE70019) and rheumatoid arthritis (RA; GDS3794) as retrieved using GEO2R.
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myeloid/ innate immune response we re-analyzed all 
available flow cytometry data of our patients acquired at 
the same moment of mRNA sample collection to quantify 
myeloid and lymphoid cell fractions. In agreement with 
the GSEA result PEBP1 anti-correlated (or showed this 
trend) with the myeloid/lymphoid balance in all centers 
tested (Figure 5). This is further supported by the 
observation that, a change in PEBP1 expression as a result 
of vaccination was significantly more often associated 
with a change of the myeloid/ lymphocyte balance in the 
opposite direction (p<0,01 by Fisher exact test; Figure 5).
Together, these data demonstrate that in patients 
doing poorly after DC vaccination, low PEBP1 levels are 
indicative of a distorted myeloid/ lymphocyte balance 
and that this may correlate with skewing of the induced 
immune response towards chronic inflammation.
DISCUSSION
We here describe PEBP1 as a novel gene whose low 
expression on blood leukocytes is associated with poor 
survival in metastatic melanoma patients receiving DC 
therapy. The association of PEBP1 with survival provides 
important clues towards the mechanisms that determine 
the success of the DC vaccine-driven immune response. 
Furthermore, PEBP1 expression on white blood cells 
may have clinical value in selecting patients who may not 
benefit from further DC treatment in its current form and 
who might be better treated with other forms of immune 
or combination therapy (for example in combination with 
immune checkpoint blockade or chemotherapy).
We tested and validated the association of PEBP1 
with survival on independent samples from different 
treatment centers. Our data indicate that low PEBP1 levels 
after DC vaccination, but not before, are associated with a 
poor survival. Interestingly, we found that in patients who 
responded poorly, PEBP1 levels decreased even further, 
whereas patients who did well demonstrated a rise in 
PEBP1 levels upon vaccination. Based on the molecular 
context in which we find PEBP1 to be expressed, we 
postulate that a decrease in PEBP1 may be indicative 
of a skewing of the (DC-vaccine-triggered) immune 
response towards chronic inflammation/ myeloid immune 
suppression rather than towards an effective anti-tumor 
response. Such a scenario would be in line with both the 
requirement for a robust adaptive response to combat the 
Table 2: GSEA for blood transcriptional modules on correlation of genes with PEBP1 expression. From the original 
microarray analysis, genes were ranked based on their correlation with PEBP1 expression and used as input for GSEA 
using blood transcriptional modules (BTMs) as gene sets. NES: normalized enrichment factor FDR: false discovery rate
Correlation 
to PEBP1
Blood Transcriptional Module # genes NES FDR q-val
Positive ENRICHED IN T CELLS (I) (M7.0) 15 2.11 0.000
T CELL ACTIVATION (I) (M7.1) 11 1.80 0.011
NUCLEAR PORE COMPLEX (M106.0) 10 1.58 0.036
REGULATION OF TRANSCRIPTION, TRANSCRIPTION FACTORS (M213) 11 1.54 0.035
Negative ENRICHED IN MONOCYTES (II) (M11.0) 95 -3.18 0.000
CELL CYCLE AND TRANSCRIPTION (M4.0) 85 -2.95 0.000
IMMUNE ACTIVATION - GENERIC CLUSTER (M37.0) 93 -2.80 0.000
MONOCYTE SURFACE SIGNATURE (S4) 48 -2.75 0.000
TLR AND INFLAMMATORY SIGNALING (M16) 29 -2.60 0.000
ENRICHED IN MONOCYTES (IV) (M118.0) 22 -2.48 0.000
MYELOID CELL ENRICHED RECEPTORS AND TRANSPORTERS (M4.3) 20 -2.40 0.000
ENRICHED IN NEUTROPHILS (I) (M37.1) 18 -2.31 0.000
ENRICHED IN MYELOID CELLS AND MONOCYTES (M81) 10 -2.03 0.000
RESTING DENDRITIC CELL SURFACE SIGNATURE (S10) 14 -2.03 0.000
REGULATION OF ANTIGEN PRESENTATION AND IMMUNE 
RESPONSE (M5.0)
31 -2.00 0.000
ENRICHED IN ANTIGEN PRESENTATION (II) (M95.0) 11 -1.83 0.001
ENRICHED IN ACTIVATED DENDRITIC CELLS (II) (M165) 11 -1.65 0.006
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tumor, and the reported high prevalence of inflammation 
and/or tumor-induced MDSCs in patients with a poor 
prognosis [15-17, 38, 39]. Indeed, in the Nijmegen cohort, 
PEBP1 levels were negatively correlated with monocytic 
MDSC numbers. These experiments that aimed to 
determine the relationship between PEBP1 and MDSC are 
however by no means conclusive, and were hampered by 
great variability in MDSCs numbers between centers. The 
use of frozen material and the non-standardized MDSC 
identification methods used limited these analyses [40]. 
Figure 5: Blood PEBP1 expression anti-correlates with the myeloid/ lymphoid balance. (A) Spearman rank correlation of 
PEBP1 expression with the myeloid/ lymphocyte (M/L) balance determined by flow cytometry at the time of sample collection for all four 
treatment centers. (B) Quantification of the direction of change of PEBP1 with respect to the M/L balance in sequential longitudinal samples 
from Copenhagen (see also figure 3).
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Going forward these analyses should be included in future 
studies. Intriguingly, and in agreement with the reported 
function and ontogeny of genes correlating and anti-
correlating with PEBP1, we found that PEBP1 expression 
levels in patient samples from all centers was inversely 
correlated with the myeloid/ lymphoid balance in PBMCs 
at the time of sample collection.
It remains to be determined whether PEBP1 is 
directly driving the skewing of T cell-mediated immunity 
towards robust anti-tumor responses, or is merely a 
bystander gene reflecting the state of the immune system. 
PEBP1, also known as RKIP, is a mostly-cytoplasmic 
protein that is widely expressed and has diverse functions 
affecting several important signaling cascades including 
NFκB, MAPK/ERK and GSK3β signaling, to regulate 
cell proliferation, migration, and activation (reviewed 
by [34, 41]). In cancer, PEBP1 expression seems mostly 
favorable to survival and, for melanoma, an inverse 
correlation between PEBP1 expression and metastases has 
been reported [31, 32]. Although we discovered a similar 
favorable association between high PEBP1 expression 
and survival, our finding is on white blood cells, not 
on tumor cells. Our results are therefore unlikely to be 
explained by an intrinsic effect of PEBP1 on tumor cells 
or their metastatic counterparts. Instead it is more likely 
that PEBP1 acts on the white blood cells themselves. 
This notion is supported by the inverse correlation of 
PEBP1 expression with the myeloid/ lymphocyte balance. 
Intriguingly, the genes inversely correlated with PEBP1 
included, and were centered around STAT3, NOTCH1, 
and MAPK1 (ERK2) (by PPI). Possibly the discriminative 
power of PEBP1 demonstrated here may relate to the 
signaling pathways associated with these molecules. 
PEBP1 expression has been reported to dampen the 
inflammatory response, acting on both ERK/MAPK and 
NFκB signaling to reduce pro-inflammatory cytokine 
release [33, 34, 42, 43]. High PEBP1 expression has 
also recently been shown to attenuate STAT3 signaling, 
which in turn has been shown to be a key factor for 
the suppressive effect of MDSCs [44–46]. MDSCs are 
postulated to dampen the immune response to tumors, 
including melanoma, and are associated with poor survival 
[38, 39, 47, 48]. The presence of chronic inflammation in 
cancer patients has been held responsible for the induction 
of MDSC via growth factors and cytokines (e.g. G- or 
GM-CSF, IL-6, TGFβ, PGE2) acting via ERK/ mTOR, 
STAT, NFκB and SMAD signaling pathways [49, 50]. 
Considering the inverse correlation between PEBP1, 
STAT3 and ERK expression identified here, it seems quite 
possible that PEBP1 acts on these signaling pathways to 
prevent/dampen excessive systemic inflammation that may 
hamper an effective adaptive immune response following 
DC vaccination. This hypothesis is supported by our 
finding that PEBP1 levels are also diminished in patient 
suffering from other diseases associated with chronic 
inflammation.
Besides regulating inflammation in general, the 
action of PEBP1 may be more sophisticated. In CD8+ 
T cells PEBP1 expression is associated with enhanced 
IFN-γ signaling downstream of the TCR [51]. PEBP1 
may thus have dual functions in inhibiting deleterious 
systemic inflammation that drives immunosuppression, 
whilst at the same time promoting adaptive responses. In 
line with this view, we find in our gene expression data 
an inverse correlation of PEBP1 with genes connected to 
innate and inflammatory responses, while genes associated 
with T cell responses positively correlate with PEBP1 
expression. Furthermore, we observed that PEBP1 is 
also highly correlated with the expression of ribosomal 
subunits suggesting PEBP1 expression to be associated 
with high protein biosynthesis capacity. This may 
facilitate an effective adaptive immune response which is 
highly dependent on the production of large amounts of 
inflammatory mediators (e.g. cytokines, antibodies) and 
immune cell expansion. Further research on the expression 
and function of PEBP1 in different immune cells is 
required to shed further light on how exactly PEBP1 
relates to the skewing of immune responses following DC 
vaccination.
Our study once more indicates that the presence of 
excessive/chronic inflammation and /or a lack of “fitness” 
of the immune system may be a severe obstacle to the 
success of DC vaccination. Suppressive and exhausted 
immune cells may hamper the effectiveness of treatment 
modalities that are aimed at inducing or boosting adaptive 
immune responses. Together, the data presented here 
and from other studies, suggest that the presence of 
chronic inflammation, MDSCs and now also low PEBP1 
expression may all represent contraindications for further 
DC vaccination in its current form. More studies are 
required to obtain detailed mechanistic insight into the 
interaction of these factors. Recent literature suggests 
that lifting this state of aberrant inflammation and 
concordant suppression of immune responses in cancer 
patients, by e.g. interfering with STAT signaling or by 
certain regiments of chemotherapy could increase the 
effectiveness of various types of immunotherapy [49, 
52, 53]. As such PEBP1 could represent a facile and 
effective blood-based biomarker to monitor whether the 
fitness of the immune system is adequate for successful 
immunotherapy.
MATERIALS AND METHODS
Patients
Clinical data and biological samples from melanoma 
patients undergoing DCs vaccination were obtained from 
the University of Erlangen, Erlangen, Germany (see Table 
1 ; www.clinicaltrials.gov NCT00053391 and [54, 55], 
from the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands (NCT00243594; NCT00243529; 
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NCT0228541 and [56–58]), from Copenhagen University 
Hospital, Herlev, Denmark (NCT00197912 and [59, 60]) 
and from the Medical University of Innsbruck (patient 
treatment not part of a clinical trial but as “compassionate 
use” according to Austrian national regulations; the use of 
cell samples from these patients for this study was approved 
by the local ethical committee (reference number AN2016-
0130/363/4.18)). All studies were approved by the local 
regulatory committees, and written informed consent was 
obtained from all patients.
For our studies, we used PBMCs and DC vaccines 
stored in biobanks collected during various previously-
performed clinical trials. Vaccination strategy in brief: all 
patients were vaccinated with monocyte-derived dendritic 
cells generated ex vivo from autologous monocytes by culture 
with GM-CSF and IL-4 and subsequently matured with a 
cytokine cocktail consisting of IL-1 beta, IL-6, TNF-alpha 
and PGE2 (see references [54–60] for center specific details 
on DC culture and the origin of used reagents; Erlangen and 
Innsbruck patients were in part not previously reported and 
center-specific details on DC generation for these patients 
are given in supplementary methods). In summary, vaccine 
DCs were either loaded with tumor antigen-derived HLA-
specific/matched peptides from P53, Survivin, Telomerase, 
MAGEA1, MAGEA3, Tyrosinase, MAGEA10, NY-ESO-1, 
MelanA, and/ or gp100, electroporated with mRNA coding 
for tumor antigens or loaded with tumor cell lysate ([30, 
54, 59–61]); supplementary Table 3). Furthermore, some 
Erlangen patients were vaccinated with moDCs exposed 
to the maturation cocktail plus soluble trimeric CD40L 
(Gross et al., manuscript submitted), and some Copenhagen 
patients received metronomic doses of cyclophosphamide 
co-therapy (supplementary Table 2, supplementary methods 
and [60]). Nijmegen and Copenhagen PBMC were 
always acquired after an initial cycle of 3 (Nijmegen) or 4 
(Copenhagen) vaccinations, at the moment of the delayed 
type hypersensitivity skin test which is routinely performed 
1 week after the last vaccination of this cycle. Additional 
patient samples from Copenhagen were collected just prior to 
vaccination or after a total 6 of vaccinations. For the Erlangen 
cohort, the timing of blood sample collection varied and was 
on average after 6 vaccinations (range 1-23 vaccinations) 
that were taken on average 39 days after the last vaccination 
(range 6-110 days). Innsbruck cohort sample collection 
was at multiple time points during ongoing vaccination as 
indicated in Supplementary Figure 6. The Erlangen and 
Innsbruck cohorts contained many fewer short-surviving 
patients which might be explained by the fact that vaccination 
continued after trial end (supplementary Table 2).
Microarray data generation
RNA was extracted from biobanked PBMCs and 
moDCs using the Ambion RNA mirvana™ extraction 
kit. RNA quality and abundance were determined using 
an Agilent 2100 Bioanalyzer and Nanodrop ND-1000 
spectrophotometer, respectively. 500ng of total RNAs 
were reverse transcribed to synthesize first- and second- 
strand complementary DNA (cDNA), purified and in vitro 
transcribed to synthesize biotin-labeled complementary 
RNA (cRNA) using the Illumina TotalPrep-96 RNA 
Amplification Kit (# 4393543 Ambion, Inc., Austin, 
TX). A total of 750ng of biotin-labeled cRNA was then 
hybridized to Illumina HumanHT-12 V3.0 expression 
BeadChips at 55C for 18 h. The hybridized BeadChip was 
washed and stained with streptavidin-Cy3 according to the 
manufacturers protocols using Illumina whole-genome 
gene expression direct hybridization assay ( #11286340 
Illumina, San Diego, California, USA). GenomeStudio 
Data Analysis Software used to visualize and analyse 
images generated. This software provides data in standard 
file formats that can be readily processed with most 
commercial and/or public accessible gene expression 
analysis software programs to identify significantly 
differentially expressed genes with pathways and networks 
involved. Raw data from BeadStudio were exported as 
text files and processed using the Bioconductor R package 
Lumi [62]. Quality controls were performed, and samples 
with incorrect parameters were discarded. The background 
was adjusted by subtracting an offset estimated based on 
the quantile of the control probes; then normalization 
was performed using log2 transformations. All further 
statistical analyses, unless otherwise specified, was 
performed on probe expression values. Raw data as well 
as normalized data for all the samples (74 PBMC samples 
and 68 matched mature moDCs samples) we used in this 
work have been deposited in the ArrayExpress repository 
with the ID E-MTAB-5201.
Microarray data statistical analysis
Survival analysis by SAM
The significance analysis of microarrays (SAM) as 
implemented in the Bioconductor R package Rsam [63] 
includes a procedure for estimating survival associated 
probes given a vector of survival months and the censoring 
status of the PBMC donor. We used a total of 74 PBMC 
samples to draw the survival analysis, keeping the 90th 
percentile FDR = 0 to exclude the presence of false 
positive survival associated probes. The resulting probes 
were then associated with a fold change by dividing their 
mean expression values in long survivors by their mean 
expression value in short survivors. A fold-change cut-off 
of 2 was then applied to restrict the number of probes.
Partial Least Square Discriminant Analysis/ 
Multivariate analysis
Gene expression was also investigated through 
the multivariate methods implemented in the R package 
mixOmics [64]. In particular, we used a partial least 
square analysis (PLS) coupled to a discriminant analysis 
(DA) to accommodate a two or three-class categorization 
of the samples . The categories we used were the above 
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mentioned ranked survival classes of long, medium and 
short survivors. Fold changes were calculated as described 
for the survival analysis by SAM and filtered at a 2 fold-
change cut-off.
Two pass / two-class SAM
For this analysis two consecutive two-class 
SAMs were drawn: in the first pass, we searched for 
a “vaccination signature” by testing for differential 
expression in PBMCs obtained from donors after 
vaccination and the mature DCs included in the vaccine. 
Since each patient received autologous in-vitro matured 
DCs, we performed a paired PBMC vs matured DC two-
class analysis. Only significant probes were analyzed in 
the second pass, consisting in an unpaired two-class (long 
vs short survivors) SAM. Also, in this case, we selected 
probes at 90th percentile FDR = 0 to statistically exclude 
the detection of false positive results. A 2 fold change cut-
off was used for further selection.
Identification of valid housekeeping reference 
genes for qPCR normalization from microarray 
data
Established housekeeping genes for qPCR 
normalization of PBMCs samples are not consistently 
reported in literature. Genes that are routinely used 
as reference genes such as GAPDH do not perform 
well on whole blood or PBMC samples [65, 66]. We 
therefore employed our microarray dataset to extract 
housekeeping genes to be used as a reference for 
qPCR. We first scanned the expression values of genes 
available in the microarray platform across all PBMC 
samples, searching for invariance (standard deviation 
< 5 %) in all genes with a reasonable deviation from 
background expression level, to avoid the selection of 
non-expressed genes. Best-performing genes were then 
further screened for absence of long/short survivors 
trends by analyzing both the significance of T-tests and 
Mann-Whitney tests, the slopes associated to a linear 
regression of long versus short survivor samples and 
maximal overlap between the long and short survivor 
samples. Via this method we isolated PBGD, EEF1A1 
and OXSR1 genes as most stably expressed genes. 
After measuring by qPCR the expression levels of these 
MA-derived three genes plus the frequently reported 
GAPDH gene in samples already used in microarrays, 
we used the procedure described by Vandesopele and 
coworkers that relies on pairwise variations across 
samples to rank HKs genes according to their stability 
and perform a progressive, stepwise elimination [67]. 
Following this selection, two reference genes were 
validated, namely OXSR1 and PBGD, and used in 
combination as reference genes for further qPCR 
analysis. All the statistics were calculated using the R 
software.
RNA isolation and quantitative PCR on patient 
PBMCs
PBMCs were obtained from each of the Center’s 
Biobanks. RNA was isolated using the RNeasy mini kit 
(Qiagen, array samples) or Trizol (Life Technologies, 
additional qPCR samples) following manufacturers 
protocol. RNA quantity was determined on NanoDrop 
2000c (Thermo Scientific) and RNA quality was 
determined via agarose gel electrophoresis. 2 ug of RNA 
was DNAse I treated to remove residual genomic DNA 
and reverse transcribed into cDNA by M-MLV reverse 
transcriptase (Life Technologies) to obtain 25ul of cDNA. 
cDNA was diluted 25x in nuclease free water. For each 
reaction, 4ul diluted cDNA, 300nM primers, 10ul SYBR 
Green (Roche) and water were added to a final volume 
of 20ul. Each sample was amplified using a CFX96 
sequence detection system (BioRad). The following qPCR 
cycling conditions were used: 50°C/2min, 95°C/10min, 
40cycles of 95°C/15s; 60°C/1min, melt analysis 60°C 
- 95°C with increment 0.5°C/5s. The gene-specific 
oligonucleotide primers used to determine the expression 
of the genes of interest are listed in supplemental table 
S4. To increase the chance of consistency qPCR primers 
were based on the MA probes with highest differential 
expression. PCR products were monitored by measuring 
the increase in fluorescence caused by binding of SYBR 
Green. Quantitative PCR data were analyzed using 
CFX96 manager and relative expression of the gene of 
interest was determined using the cycle threshold method 
(Livak KJ, 2001) with PBGD and OXSR1 as reference 
genes.Statistical analysis of normalized qPCR data was 
performed using graph pad prism software using the 
statistical tests indicated in the figure legends.
Gene Set Enrichment analysis of genes 
correlating with PEBP1 expression, Protein-
Protein Interaction, and Gene Ontology analysis
Using the full microarray dataset, the Pearson 
correlation and p-value of all probes in relation to 
PEBP1 expression on the array was determined in the R 
programming environment. Genes were ranked based on 
their log-transformed Pearson correlation coefficient, and 
this ranked list was used as input for Gene Set Enrichment 
Analysis (GSEA) against the blood transcriptional 
modules described by LI at al. [35–37]. Alternatively a 
ranked list of the correlation of human genes with PEBP1 
in the immune-navigator database ((http://sysimm.ifrec.
osaka-u.ac.jp/immuno-navigator/) was used as input. 
For GSEA standard operating setting was applied taking 
into account only the highest ranking gene sets with a 
minimum 10 genes.
To build PPI networks the top 500 of genes, 
correlating or anti-correlating with PEBP1 expression 
were loaded into STRING database (http://string-db.
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org) to find any direct (physical) or indirect (functional) 
associations [68]. Using this database we simultaneously 
mapped genes on gene-ontologies. PPIs with a high 
confidence score were loaded in Biolayout express3D for 
visualization (http://www.biolayout.org/) [69].
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